### **Ig usage data and statistics – September 2024**

#### Overview

Recent data and statistics on Ig use in Australia are presented below, providing a snapshot of Ig usage and trends in Australia. To accommodate data entry and reconciliation requirements, data are usually published approximately three months in arrears.

#### Snapshot

The snapshot provides an overview of the information that is further detailed in the graphs and tables that follow.

|  |  |
| --- | --- |
| **Patients** | **BloodSTAR** |
| 15,806 | 1,300 |
| Total Patients September 2024 | Authorisations in September 2024 |
| 828 | 27,124 |
| New Patients who had Dispenses in September 2024 | Dispense Events in September 2024 |
| **Product Issued** | **Ig Use** |
| 807,016 | 777,832 |
| Grams Issued in September 2024 | Grams Dispensed in September 2024 |
| $88 Million | 204,747 g  Acquired-hypogammaglobulinaemia — haematological malignancy or post HSCT |
| Expenditure in September 2024 | Grams Highest Medical Condition in September 2024 |

#### Ig use

**Year to date September 2024 - %** **variation year on year by jurisdiction.** This graph shows a cumulative percentage changes in Ig issued, nationally and by jurisdiction, for the current financial year to date as compared to the same period in the previous financial year.

**Issues of Ig per 1,000 population by jurisdiction.** This graph shows the amount of Ig issued (grams) per 1,000 population nationally and by jurisdiction for the previous 3 months.

**Ig use by medical condition.** This graph shows the medical conditions which account for the highest use (grams dispensed) of Ig products.

#### 

#### Product issued

**Monthly expenditure on Ig.** This graph shows the cost of Ig products issued over the last 9 months.

**Monthly usage of Ig.** This graph shows the amount of domestic and imported Ig products issued (grams) in the last 9 months.

**BloodSTAR**

**Patients.** This graph shows the total number of patients receiving Ig and the number of new patients over the last 9 months.

**Authorisation and dispense events.** This graph shows the number of new authorisation requests approved and the number of dispense events over the last 9 months.

|  |  |  |
| --- | --- | --- |
| **Number of registered facilities** | **Number of registered SCIg approved facilities** | **Total number of registered users** |
| 1,209 | 119 | 27,012 |

### **More information**

Annual reports on the issue and usage of immunoglobulin provide further information. For context and links, see: [Immunoglobulin usage and data | National Blood Authority](https://www.blood.gov.au/blood-products/immunoglobulin-products/immunoglobulin-usage-and-data).

In addition:

BloodSTAR Facility Administrators can access reports about their facility’s Ig usage through the reports function in BloodSTAR.

Jurisdictional Reports are available to Jurisdictional Blood Committee (JBC) representatives and their nominees. These provide information on the Ig dispensed for each State and Territory.

The NBA will also consider specific requests for data. All requests will be considered in line with the NBA’s Data and Information Governance Framework. More information, including about how to submit data requests, is available [here](https://www.blood.gov.au/data-and-research/data-and-reporting).